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TherapySummary
Background: In this retrospective Italian study, which involved all major national interstitial
lung diseases centers, we evaluated the effect of pirfenidone on disease progression in pa-
tients with IPF.
Methods: We retrospectively studied 128 patients diagnosed with mild, moderate or severe
IPF, and the decline in lung function monitored during the one-year treatment with pirfenidone
was compared with the decline measured during the one-year pre-treatment period.
Results: At baseline (first pirfenidone prescription), the mean percentage forced vital capacity
(FVC) was 75% (35e143%) of predicted, and the mean percentage diffuse lung capacity (DLCO)
was 47% (17e120%) of predicted. Forty-eight patients (37.5%) had mild disease (GAP index
stage I), 64 patients (50%) had moderate IPF (stage II), and 8 patients (6.3%) had severe disease
(stage III).
In the whole population, pirfenidone attenuated the decline in FVC (pZ 0.065), but did not
influence the decline in DLCO (p Z 0.355) in comparison to the pre-treatment period.
Stratification of patients into mild and severe disease groups based on %FVC level at baseline
(>75% and 75%) revealed that attenuation of decline in FVC (p Z 0.002) was more pro-
nounced in second group of patients. Stratification of patients according to GAP index at base-
line (stage I vs. II/III) also revealed that attenuation of decline in lung function was more
pronounced in patients with more severe disease.
Conclusions: In this national experience, pirfenidone reduced the rate of annual FVC decline
(p Z 0.065). Since pirfenidone provided significant treatment benefit for patients with
moderate-severe disease, our results suggest that the drug may also be effective in patients
with more advanced disease.
ª 2015 Elsevier Ltd. All rights reserved.Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic and devas-
tating pulmonary disease that leads to respiratory failure
and death within few years of diagnosis [1]. Since 2001, the
search for effective treatment has involved a large number
of clinical trials. Although most of the investigational
agents failed to provide significant success, some trials led
to significant developments in the treatment of the dis-
ease. In 2011, pirfenidone, a novel antifibrotic agent, was
the first drug to be approved for the treatment of IPF in
Europe. Pirfenidone has been available in Japan since 2008
[2,3]. The approval by the European Medicine Agency (EMA)
was based on key clinical studies supporting the efficacy of
pirfenidone in reducing lung function deterioration in IPF
patients [4]. Results from the ASCEND study [5] confirmed
that pirfenidone reduced disease progression in patients
with IPF, as reflected by lung function, exercise tolerance,
and progression-free survival; the treatment was associated
with an acceptable side-effect profile and fewer deaths.
Recently, both pirfenidone and the kinase inhibitor
nintedanib received approval from the U.S. Food and Drug
Administration for the treatment of IPF [5,6].
Pirfenidone has been evaluated in several randomized
multicenter trials [2e5]. However, clinical trials are often
conducted on IPF patient populations that are not truly
representative of those seen in daily clinical practice:
therefore, the efficacy of pirfenidone in a general popula-
tion of patients with IPF has not yet been fully investigated.
The aim of this study was to investigate the effect of
pirfenidone in the treatment of IPF in real-life clinical
practice.For this reason, we analyzed the data on the use of
pirfenidone that have been accumulated by the major
referral centers for interstitial lung disease in Italy that
participated to the European Named Patient Access Pro-
gram (NPP). This program, which was supported by the
company (InterMune inc.) responsible for the development
and commercialization of pirfenidone in Europe, allowed
qualified physicians to make the newly approved pirfeni-
done available (free of charge) to their IPF patients, pro-
vided that pre-specified medical criteria and conditions
were met, before it was commercially available within a
given European country.Material and methods
Population and study design
This was an observational, retrospective, multicenter,
unsponsored study, which involved 12 Italian interstitial
lung disease centers distributed across the country.
For our study, we evaluated the data obtained from the
12 centers that enrolled at least 3 patients in the NPP
program.
We reviewed clinical records of those IPF patients whose
functional evaluation was documented for at least one year
before and one year after initiation of pirfenidone therapy.
Patients who received steroids, azathioprine, or N-ace-
tylcysteine (NAC) before the initiation of pirfenidone ther-
apy were not excluded from the analysis. Patients who were
previously enrolled in the CAPACITY trials and subsequently
entered the NPP program were also included in the analysis.
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gression of IPF, we analyzed the variation of various pulmo-
nary function parameters (%FVC, DLCO, %DLCO and the
distancewalked at 6MWT) during the one-year period before
(the pretreatment period) and the one-year period after
initiation of the treatment with pirfenidone (the follow-up
period). In each patient, the decline in lung function expe-
rienced over the follow-up period was compared to the one
monitored over the pretreatment period, irrespective of any
use of steroids, azathioprine, or NAC. Our analysis was based
on the assumption that, other than pirfenidone, therewas no
effective treatment for IPF and, therefore, the use of any of
the above-mentioned drugs during the pretreatment period
would not have influenced the course of disease in a clinically
meaningful way [7,8].
Moreover, in order to investigate whether the response
to treatment could vary depending upon disease severity,
the effect of pirfenidone was evaluated in patients strati-
fied into mild and severe disease groups based on their
percent predicted FVC values (%FVC) and GAP stage [9] at
treatment initiation (the baseline).
This study was approved by the San Giuseppe Hospital
Ethical Committee (protocol number 27/13).Table 1 Patients’ characteristics (N Z 128).
Variable Levels N (%)
Center Catania 14 (10.9)
Forlı` 13 (10.2)
Milano 12 (9.4)
Modena 9 (7.0)
Monza 9 (7.0)
Napoli 2 (1.6)
Padova 7 (5.5)
Roma 1 8 (6.3)
Roma 2 5 (3.9)
Siena 6 (4.7)
Torino 18 (14.1)
Trieste 25 (19.5)
Gender Female 32 (25.0)
Male 96 (75.0)
Age at baseline (years)a 60 17 (13.3)
61e65 20 (15.6)
65þ 91 (71.1)
Smoking status Ex-smoker 97 (75.8)
Non smoker 27 (21.1)
Smoker 4 (3.1)
Histological diagnosis No 96 (75.0)
Yes 32 (25.0)
Cortisone No 53 (41.4)
Yes 75 (58.6)
Azathioprine No 97 (75.8)
Yes 31 (24.2)
N-Acetylcysteine No 75 (58.6)
Yes 53 (41.4)
Time from diagnosis of
IPF to initiation of
pirfenidone therapy (years)b
<1 43 (33.6)
1e2 40 (31.2)
>2 45 (35.2)
a Mean age: 69 years (SD: 7 years).
b Mean time from diagnosis of pulmonary fibrosis to initiation
of treatment with pirfenidone: 2.0 years (SD: 1.8 years).Statistical analysis
Due to the retrospective nature of this study, the lung
function parameters were not collected using the same
time schedule among all patients and centers.
Therefore, the number of assessments performed during
the pretreatment and the follow-up periods varied among
patients, ranging from a minimum of three assessments (1
performed one year before initiation of pirfenidone ther-
apy, 1 performed at therapy initiation, and 1 performed
one year after treatment initiation) in 17 patients, to more
than six assessments in 20 patients. In order to efficiently
use all data, we opted to include in the statistical analysis
all lung function measurements (when available) collected
during the 2-year time frame, using a regression approach.
Mixed linear models for unbalanced repeated measures
were used to assess the trends of spirometry parameters and
the 6MWT distance before and after pirfenidone therapy. For
these models, we used lung function parameters measured
during the one-year period before starting treatment with
pirfenidone (the pretreatment period), at treatment initia-
tion (the baseline), and during the one-year period after the
initiation of pirfenidone therapy (the follow-up period).
Two trend terms were estimated: b1, related to the
trend over the pretreatment period, and b2, related to the
follow-up period. The predicted values at one year before
and one year after treatment entry were estimated from
the models, and changes in percent predicted values during
the two one-year periods were calculated.
The null hypothesis that there was no difference in the
two one-year trends (i.e. b1 Z b2) or, equivalently, that
changes in percent predicted values during the pretreat-
ment period were equal to changes in percent predicted
values during the follow-up period was tested.
To evaluate the effect of the administration of lower
than standard doses of pirfenidone (2403 mg) on the out-
comes, we introduced in the models an interaction termbetween dose reduction (dichotomized as indicated at a
given visit or absent) and the trend over the year following
pirfenidone initiation.
Similarly, the %FVC values measured at baseline (strati-
fied by > 75% and 75% of predicted) and the GAP score at
baseline (stratified by stage I and stage II/III) were intro-
duced in the models as binary covariates, and their inter-
action terms with trends were evaluated in order to test
the homogeneity of difference in percent changes among
strata.
Statistical analyses were performed with SAS version 9.3
(SAS Institute Inc, Cary, NC).
Results
A total of 128 consecutive patients who were enrolled from
12 centers were evaluated in our analysis. Patients’ char-
acteristics are reported in Table 1. Most of the patients were
men (75%), ex smokers (75.8%), with a clinical-radiological
diagnosis of IPF (75%), and aged more than 65 years
(71.1%). Many of these patients had received corticosteroids
(58%), NAC (41%), or azathioprine (24%), sometimes in
Table 3 GAP index and stage of patients at the time of
initiation of therapy with pirfenidone (baseline).
Predictor N (%) Median,
(Minemax)
G e Gender Female 32 (25.0)
Male 96 (75.0)
A e Age class 60 17 (13.3)
61e65 20 (15.6)
65þ 91 (71.1)
P e Physiology % FVC
75 59 (46.1)
50e75 67 (52.3)
<50 2 (1.6)
%DLCO
>55 26 (20.3)
36e55 75 (58.6)
35 19 (14.8)
N/A 8 (6.3)
GAP index e 4 (1e6)
Stage I (GAP index 0e3) 48 (37.5)
II (GAP index 4e5) 64 (50.0)
III (GAP index 6e8) 8 (6.3)
N/Aa 8 (6.3)
a N/A: not available.
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period elapsed between the diagnosis of IPF and the initia-
tion of pirfenidone therapy was 2.0 years (SD: 1.8 years): in
particular, the time lapse was less than one year for 43 pa-
tients, it ranged between 1 and 2 years for 40 patients, and it
was greater than 2 years for the remaining 45 patients.
The pulmonary function profiles of our patient popula-
tion at baseline are illustrated in Table 2. The mean FVC
was 75% (SD  18) of predicted value, the mean DLCO was
47% (SD  15) of predicted, and the average distance
walked during the 6MWT in patients not requiring supple-
mental oxygen was 442 meters (SD  101).
Stratification of the population based on gender, age, %
FVC, %DLCO and GAP severity index at baseline is reported
in Table 3.
Effects of pirfenidone therapy are described in Table 4.
Over the one-year pretreatment period, patients experi-
enced a mean decrement of 6.3% in percent predicted FVC:
the average FVC dropped from 80% (95% IC: 77e84) to 75%
(95% IC: 72e79) of predicted. Over the follow-up period, a
reduction in the mean decline in FVC was observed, with a
mean decrement of only 1.3% in the percent predicted FVC:
the average FVC decreased from 75% (95% IC: 72e79) to 74%
(95% CI: 70e77) of predicted (see also Fig. 1). The differ-
ence in percent changes between the pretreatment and the
follow-up period was 4.9% (p-value Z 0.065; see Table 1).
There was no significant difference in %DLCO and in the
distance walked during the 6MWT before and after treat-
ment with pirfenidone.
Only 22 patients out of 128 (17,1%) were treated with
lower than the standard dose of pirfenidone (2403 mg/day);
however, such dose reduction did not influence the out-
comes observed during the one-year follow-up period.
The effects of pirfenidone therapy in subgroups of pa-
tients stratified by disease severity at baseline are illus-
trated in Table 5.
The attenuation in the rate of FVC decline was more
pronounced in the group of patients with more severe dis-
ease (FVC  75% of predicted) at baseline (p-value for ho-
mogeneity of difference between strata Z 0.002). In
patients with FVC >75% of predicted, the pirfenidone
therapy did not influence the decline in FVC: the mean
decrement of 1.1% monitored over the pretreatment periodTable 2 Spirometry parameters and 6MWT distance at the
time of initiation of therapy with pirfenidone (baseline).
N Mean (SD) Minemax
% FVC 128 75 (18) 35e143
DLCO 120 11.27 (4.02) 1.52e26.40
% DLCO 120 47 (15) 17e120
Distance (m)
(without suppl. O2)
a
63 442 (101) 250e750
Distance (m)
(with suppl. O2)
b
25 360 (86) 150e490
FEV1/FVC
(Tiffenau Index)
119 83 (9) 55e120
a Five patients did not complete the 6MWT (not included in
the analyses).
b Three patients did not complete the 6MWT (not included in
the analyses).did not statistically differ from the 3.3% decrement expe-
rienced over the follow-up period (p Z 0.332). On the
contrary, in patients with FVC 75% of predicted, the pir-
fenidone therapy completely prevented further decline in
FVC: in fact, these patients experienced a mean decrement
of 12.7% in percent predicted FVC over the pretreatment
period, while they experienced no decrement (mean
change Z 0%) over the follow-up period (p Z 0.006).
No differences were observed between these two sub-
groups of IPF patients in terms of DLCO, %DLCO, and dis-
tance walked during the 6MWT before and after treatment
with pirfenidone.
Stratification of patients using GAP index at baseline
(stage I vs. II/III) also revealed that, compared to patients
with less advanced disease (GAP stage I), those with more
advanced disease (GAP stages II and III) could benefit the
most by the administration of pirfenidone in terms of
reduction of decline in FVC (p-value for homogeneity of
difference between strataZ 0.041). Moreover, a benefit in
terms of 6MWT distance was observed in those patients
with stage II/III IPF who received supplemental oxygen
during the test. For more details, see Table 6.
It is worth to note that in 16 out of 128 patients (12.5%),
the pirfenidone therapy was associated with an improve-
ment in FVC of more than 10% (data not shown). Interest-
ingly, 3 of these patients had a histological diagnosis of IPF:
findings obtained from these patients certainly deserve
further investigation.Discussion
In this study, the effect of pirfenidone on annual rate of
decline in %FVC has been retrospectively analyzed in 128
Italian patients with IPF: our results indicated that
Table 4 Spirometric parameters and 6MWT distance measured one year before pirfenidone therapy initiation (1-yr before), at
the time of treatment entry (baseline), and one year after therapy initiation (1-yr after).
Parameter Time Meana (95% CI) Change (%) Difference in
changes (%)
p-valued
% FVC 1-yr before 80 (77, 84) e e
Baseline 75 (72, 79) 6.3b e
1-yr after 74 (70, 77) 1.3c 4.9 0.065
DLCO 1-yr before 12.28 (11.45, 13.11) e e
Baseline 11.27 (10.60, 11.95) 8.2b e
1-yr after 9.78 (8.90, 10.66) 13.2c 5.0 0.355
% DLCO 1-yr before 51 (48, 55) e e
Baseline 47 (44, 49) 7.8b e
1-yr after 40 (37, 43) 14.9c 7.1 0.249
6MWT distance
(without suppl.O2)
1-yr before 452 (423, 481) e e
Baseline 433 (411, 454) 4.4b e
1-yr after 421 (393, 450) 2.6c 1.8 0.661
6MWT distance
(with suppl. O2)
1-yr before 403 (340, 466) e e
Baseline 358 (331, 386) 11.1b e
1-yr after 362 (330, 394) 1.0c 12.1 0.280
a Based on predicted values at 1-yr before, at baseline and at 1-yr after therapy initiation, as estimated from a linear mixed model.
b % change during pre-treatment period: (baseline e 1yr before)/(1yr before).
c % change during follow-up period: (1yr after -baseline)/(baseline).
d Based on the null hypothesis that % change over pre-treatment period Z % change over follow-up period.
908 S. Harari et al.pirfenidone reduced the decline in %FVC, and this effect
was more pronounced in patients with moderate to severe
disease (%FVC 75%). No consistent changes in DLCO have
been observed.
Several multicenter randomized trials have investigated
the efficacy of pirfenidone [2e5]. However, limited data
are available on the use of this drug in daily clinical prac-
tice. A real-life experience with pirfenidone in Japanese
patients with IPF has been described by Okuda et al. [10]Figure 1 Mean FVC percentage (and 95% CI) at 1-yr before, at ba
the linear mixed model.Oltmanns et al. [11] reported their findings from an
observational cohort study conducted on a German tertiary
referral center for interstitial lung disease. Chauduri et al.
[12] described their results on pirfenidone tolerability and
its effects on the decline of %FVC and %DLCO in UK patients
involved in the NPP program. However, all these retro-
spective trials were conducted in a single center and on
small patient populations. In our study, we reviewed data
obtained from a national multicenter Italian experience,seline and at 1-yr after pirfenidone initiation, estimated from
Table 5 Spirometric parameters and 6MWT distance measured one year before pirfenidone therapy initiation (1-yr before), at the time of treatment entry (baseline), and
one year after therapy initiation (1-yr after) in patients stratified by percent predicted FVC (75% and >75%) at baseline.
Parameter Time FVC at baseline >75% of predicted FVC at baseline 75% of predicted
Meana (95% CI) Change (%) Difference in
change (%)
p-valued Meana (95% CI) Change
(%)
Difference in
change (%)
p-valued
FVC (% of predicted) 1-yr before 92 (88, 95) e e 71 (67, 74) e e
baseline 91 (88, 94) 1.1b e 62 (59, 65) 12.7b e
1-yr after 88 (84, 92) 3.3c 2.2 0.332 62 (58, 65) 0.0c 12.7 0.006
p-value for homogeneity of difference in % changes between strata: 0.002
DLCO 1-yr before 13.22 (12.05, 14.39) e e 11.46 (10.33, 12.58) e e
baseline 12.33 (11.38,13.29) 6.7b e 10.34 (9.44, 11.24) 9.8b e
1-yr after 11.24 (9.98, 12.50) 8.8c 2.1 0.792 8.49 (7.31, 9.67) 17.9c 8.1 0.317
p-value for homogeneity of difference in % changes between strata: 0.618
DLCO (% of predicted) 1-yr before 55 (50, 60) e e 48 (43, 52) e e
baseline 51 (47, 55) 7.3b e 43 (39, 46) 10.4b e
1-yr after 45 (41, 50) 11.8c 4.5 0.605 35 (30, 39) 18.6c 8.2 0.279
p-value for homogeneity of difference in % changes between strata: 0.707
Distance (without suppl. O2) 1-yr before 479 (438, 520) e e 427 (385, 468) e e
baseline 448 (418, 478) 6.5b e 417 (387, 448) 2.2b e
1-yr after 457 (420, 495) 2.1c 8.5 0.134 381 (340, 422) 8.8c 6.6 0.339
p-value for homogeneity of difference in % changes between strata: 0.084
Distance (with suppl. O2) 1-yr before 414 (301, 526) e e 401 (324, 478) e e
baseline 342 (296, 387) 17.4b e 368 (333, 403) 8.3b e
1-yr after 367 (309, 425) 7.3c 24.7 0.248 360 (321, 399) 2.0c 6.3 0.611
p-value for homogeneity of difference in % changes between strata: 0.453
a Based on predicted values at 1-yr before, at baseline and at 1-yr after therapy initiation, as estimated from a linear mixed model.
b % change during pre-treatment period: (baseline e 1yr before)/(1yr before).
c % change during follow-up period: (1yr after -baseline)/(baseline).
d Based on the null hypothesis that % change over pre-treatment period Z % change over follow-up period.
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Table 6 Spirometric parameters and 6MWT distance measured one year before pirfenidone therapy initiation (1-yr before), at the time of treatment entry (baseline), and
one year after therapy initiation (1-yr after) in patients stratified by GAP stage (I and II/III) at baseline.
Stage I at baseline Stage II/III at baseline
Parameter Time Meana (95% CI) Change (%) Difference in
change (%)
p-valued Meana (95% CI) Change (%) Difference in
change (%)
p-valued
FVC (% of predicted) 1-yr before 87 (82, 93) e e 77 (72, 81) e e
Baseline 85 (80, 89) 2.3b e 70 (66, 74) 9.1b e
1-yr after 81 (75, 86) 4.7c 2.4 0.713 69 (64, 73) 1.4c 7.7 0.007
p-value for homogeneity of difference in % changes between strata: 0.041
DLCO 1-yr before 13.96 (12.74, 15.17) e e 11.21 (10.17, 12.24) e e
Baseline 13.00 (12.01, 13.99) 6.9b e 10.11 (9.30, 10.92) 9.8b e
1-yr after 11.20 (9.83, 12.56) 13.8c 7.0 0.305 8.79 (7.67, 9.90) 13.1c 3.2 0.739
p-value for homogeneity of difference in % changes between strata: 0.570
DLCO (% of predicted) 1-yr before 58 (53, 63) e e 47 (43, 51) e e
Baseline 54 (51, 58) 6.9b e 41 (38, 44) 12.8b e
1-yr after 46 (41, 50) 14.8c 7.9 0.113 35 (31, 39) 14.6c 1.9 0.897
p-value for homogeneity of difference in % changes between strata: 0.259
Distance (without suppl. O2) 1-yr before 456 (413, 498) e e 447 (406, 487) e e
Baseline 437 (404, 470) 4.1b e 430 (400, 459) 3.8b e
1-yr after 438 (393, 482) 0.1c 4.2 0.513 405 (365, 444) 5.8c 2.0 0.771
p-value for homogeneity of difference in % changes between strata: 0.497
Distance (with suppl. O2) 1-yr before 357 (270, 445) e e 464 (363, 566) e e
Baseline 389 (333, 444) 8.8b e 341 (307, 374) 26.7b e
1-yr after 329 (262, 397) 15.3c 24.1 0.207 367 (329, 406) 7.9c 34.5 0.021
p-value for homogeneity of difference in % changes between strata: 0.013
a Based on predicted values at 1-yr before, at baseline and at 1-yr after therapy initiation, as estimated from a linear mixed model.
b % change during pre-treatment period: (baseline e 1yr before)/(1yr before).
c % change during follow-up period: (1yr after -baseline)/(baseline).
d Based on the null hypothesis that % change over pre-treatment period Z % change over follow-up period.
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and was conducted on a large cohort of IPF patients who
received long-term treatment with pirfenidone.
In our patient population, the use of corticosteroids,
azathioprine, or NAC was rather common during the pre-
treatment period; however, since it has been largely
demonstrated that these drugs are ineffective in IPF
[7,8,13,14], we assumed that the use of these medications
had no influence on the course of disease.
The results obtained from our study indicated that pir-
fenidone attenuated the decline in FVC in IPF patients;
compared to the decline observed during the pretreatment
period, the attenuation of decline in %FVC almost reached
statistical significance (p Z 0,06).
Stratification of patients into mild and severe disease
groups based on %FVC level at baseline (75%, n Z 69
patients, or > 75%, n Z 59) revealed that patients with
advanced IPF could benefit the most from pirfenidone
therapy: in fact, in these patients the treatment
completely prevented further decline of %FVC. FVC is the
most commonly employed and accepted endpoint in clinical
trial for the evaluation of disease progression [15e19].
The study of Okuda et al. [10] showed that patients who
had experienced the most severe decline in FVC during the
6-month period prior to the therapy initiation were those
who could benefit the most from the treatment. The more
recent study of Loeh et al., [20] which was also conducted
in a real-life setting, confirmed that patients with a clear
progression of disease before pirfenidone therapy showed
an even more favorable course under pirfenidone treat-
ment. In our experience, a different influence of pirfeni-
done treatment based on disease progression before
initiation of therapy was not observed (data not shown).
Last but not least, our data suggest that pirfenidone
might be useful also in more severe stages of IPF.
Stratification of patients into mild and severe disease
groups based on GAP staging system gave similar results,
thus confirming that patients with more severe IPF at
baseline (stages GAP II and III) would benefit the most from
pirfenidone treatment.
To our knowledge, this is the first study describing the
experience with pirfenidone, the first antifibrotic therapy
approved for the treatment of IPF, in a large multicenter
study conducted in a real-life setting. Loeh et al. [20]
conducted a retrospective analysis in two large indepen-
dent IPF cohorts in Germany and Italy but ours is the first
national study really multicenter, including the 12 major
interstitial lung disease centers in Italy.
The results from this experience outlined a clinical
profile of Italian patients with IPF similar to that described
in the international guidelines and in clinical trials [1,5]. In
this study, patients who received pirfenidone did not
necessarily presented with specific medical conditions and
criteria required for the enrollment in randomized trial.
However, the physiological and epidemiological profiles of
our IPF patients were similar to those of patients enrolled in
the ASCEND trial [5]. Compared to that trial, our study was
conducted on a smaller study population; moreover, the
study design was different. Nevertheless, our results are in
agreement with the findings of the ASCEND study, and
support the efficacy of pirfenidone in reducing the decline
in FVC in patients with IPF.In addition, our study provides new and important re-
sults on the efficacy of pirfenidone in IPF patients with
more severe impairments of lung function (as defined based
on the %FVC and GAP stage at baseline): to our knowledge,
this evaluation has never been performed before. Inter-
estingly, 12.5% of patients experienced an improvement in
predicted percent FVC greater than 10%. So far, improve-
ments of pulmonary function following pirfenidone treat-
ment have been observed in a few cases; in our study, such
improvement was observed in a quite large number of pa-
tients. Thus, the question arises on whether this may
reflect the presence of an alternative diagnosis or indicate
that pirfenidone therapy may be more effective in some
subpopulations of IPF patients; however, this issue will be
addressed in further investigations.
The main strength of our observational study is that we
investigated the effect of pirfenidone therapy in a large
multicenter national cohort of patients with IPF in real-
world settings.
Our study has several limitations. First of all, it is a
retrospective study, and therefore it has the typical dis-
advantages of this kind of medical investigations. Second,
there was no control over the procedures adopted by phy-
sicians of the centers participating to the NPP program to
document medical records and select diagnostic modalities
(as a matter of fact, 75% of our patient population had a
clinical/radiological diagnosis).
It cannot be ruled out that some patients with a diag-
nosis of non-specific interstitial pneumonia (NSIP) or
fibrotic NSIP were also enrolled in the program. Neverthe-
less, this is not necessary a disadvantage, and outlines the
efficacy of pirfenidone; as a matter of fact, fibrotic NSIP is
probably often managed as usual interstitial pneumonia
(UIP) in daily practice. Another limitation of this study is
the lack of data on adverse events, toxicities and mortality
that, however, were not the objective of our study. Some
negative effects of therapies received during the pre-
treatment period, including the combination of steroids,
azathioprine, or N-acetylcysteine e which is known to be
associated with an increased risk of major adverse events
[7,14] e cannot be excluded. However, only 21% of patients
had been treated with a combination of these three med-
ications: thus, it seems unlikely that this therapy had sig-
nificant impact on safety outcomes.Conclusions
In conclusion, the results of this retrospective Italian
multicenter experience conducted on IPF patients in a real-
life setting confirm that pirfenidone reduces the decline in
FVC, a surrogate marker of mortality [16,17], and suggest
that the drug may be also effective in patients with more
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